Retagliptin Explained

Legal Status:	Investigational
Cas Number:	1174122-54-3
Pubchem:	44193830
Unii:	328C4R3P9L
Drugbank:	DB14898
Chembl:	4297435
Chemspiderid:	57583801
Stdinchi:	1S/C19H18F6N4O3/c1-32-17(31)16-14-8-28(2-3-29(14)18(27-16)19(23,24)25)15(30)6-10(26)4-9-5-12(21)13(22)7-11(9)20/h5,7,10H,2-4,6,8,26H2,1H3/t10-/m1/s1
Stdinchikey:	WIIAMRXFUJLYEF-SNVBAGLBSA-N
Smiles:	COC(=O)C1=C2CN(CCN2C(=N1)C(F)(F)F)C(=O)C[C@@H](CC3=CC(=C(C=C3F)F)F)N
Iupac Name:	Methyl 7-[(3''R'')-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(trifluoromethyl)-6,8-dihydro-5H-imidazo[1,5-''a'']pyrazine-1-carboxylate
C:	19
H:	18
F:	6
N:	4
O:	3

Retagliptin is a DPP-4 inhibitor studied for the treatment of type 2 diabetes.^{[1] [2] [3]}

Notes and References

1. Meng . Xiangjun . Cai . Lanlan . Ren . Tianming . Sun . Dong . Gu . Jingkai . Simultaneous quantitative analysis of retagliptin and its main active metabolite in human multiple matrices by liquid chromatography tandem mass spectrometry . Analytical Methods . 2018 . 10 . 18 . 2108–2114 . 10.1039/C8AY00040A . en . 1759-9679.
2. Hu . Chao . Zheng . Jing . Miao . Jia . Liu . Fang . Hu . Ting-Ting . Gu . Jing-Kai . Shu . Shi-Qing . Wang . Ying . Zhu . Xiao-Hong . Liang . Mao-Zhi . [Pharmacokinetics of Phosphate Retagliptin Tabletin in Patients with Renal Dysfunction] ]. Sichuan da Xue Xue Bao. Yi Xue Ban = Journal of Sichuan University. Medical Science Edition . 2018 . 49 . 1 . 74–80 . 29737094 . 1672-173X.
3. Cahn . Avivit . Cernea . Simona . Raz . Itamar . An update on DPP-4 inhibitors in the management of type 2 diabetes . Expert Opinion on Emerging Drugs . 2016 . 21 . 4 . 409–419 . 10.1080/14728214.2016.1257608. 27809608 . 45825587 .